Maximilian Richter, Lena Sonnow, Amir Mehdizadeh-Shrifi, Axel Richter, Rainer Koch, Alexander Zipprich
{"title":"德国结直肠癌肿瘤认证系统-单个认证中心与国家和国际注册数据的相对存活率。","authors":"Maximilian Richter, Lena Sonnow, Amir Mehdizadeh-Shrifi, Axel Richter, Rainer Koch, Alexander Zipprich","doi":"10.1515/iss-2021-0002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison.</p><p><strong>Methods: </strong>Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR).</p><p><strong>Results: </strong>Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001).</p><p><strong>Conclusions: </strong>Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.</p>","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"6 2","pages":"67-73"},"PeriodicalIF":1.7000,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/iss-2021-0002","citationCount":"5","resultStr":"{\"title\":\"German oncology certification system for colorectal cancer - relative survival rates of a single certified centre vs. national and international registry data.\",\"authors\":\"Maximilian Richter, Lena Sonnow, Amir Mehdizadeh-Shrifi, Axel Richter, Rainer Koch, Alexander Zipprich\",\"doi\":\"10.1515/iss-2021-0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison.</p><p><strong>Methods: </strong>Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR).</p><p><strong>Results: </strong>Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001).</p><p><strong>Conclusions: </strong>Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.</p>\",\"PeriodicalId\":44186,\"journal\":{\"name\":\"Innovative Surgical Sciences\",\"volume\":\"6 2\",\"pages\":\"67-73\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2021-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1515/iss-2021-0002\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Innovative Surgical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/iss-2021-0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovative Surgical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/iss-2021-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 5
摘要
目的:通过国内和国际比较,评估德国专业肿瘤中心的认证如何影响结直肠癌(CRC)患者的相对生存。方法:2007年至2013年,在汉诺威医学院(MHH)的学术教学医院希尔德斯海姆医院(Hildesheim Hospital)接受治疗的675例结直肠癌患者。整个患者组的随访一直持续到2014年。为了获得国际数据,进行了seer数据库检索。148,957例患者在12个月、36个月和60个月后的相对生存率与我们的数据进行了比较。对于国家生存数据,我们将我们的生存率与慕尼黑癌症登记处(MCR)的41988名患者进行了比较。结果:与国内和国际癌症登记数据相比,我们机构的肿瘤晚期相对生存率更高。在全国范围内,我们发现低期CRC (UICC I和II)、结肠癌和直肠癌的生存率变化很小。晚期结直肠癌肿瘤分期(UICC IV)的相对生存率存在显著差异,直肠癌在12个月、36个月和60个月后的相对生存率差异更为明显(Hildesheim医院:89.9、40.3、30.1%;慕尼黑癌症登记处(MCR): 65.4, 28.7, 16.6%)。CRC的国际比较显示,在我们的机构,晚期肿瘤患者在12个月后的相对生存率显著更高(77% vs. 54.9%;结论:我们的研究结果表明,晚期结直肠癌患者尤其是直肠癌患者从认证肿瘤中心的多学科和指南导向治疗中获益最多。为了更好地评估癌症治疗并改进国内和国际比较,有必要建立一个集中的国家癌症登记处。
German oncology certification system for colorectal cancer - relative survival rates of a single certified centre vs. national and international registry data.
Objectives: To evaluate how the certification of specialised Oncology Centres in Germany affects the relative survival of patients with colorectal cancer (CRC) by means of national and international comparison.
Methods: Between 2007 and 2013, 675 patients with colorectal cancer, treated at the Hildesheim Hospital, an academic teaching hospital of the Hannover Medical School (MHH), were included. A follow-up of the entire patient group was performed until 2014. To obtain international data, a SEER-database search was done. The relative survival of 148,957 patients was compared to our data after 12, 36 and 60 months. For national survival data, we compared our rates with 41,988 patients of the Munich Cancer Registry (MCR).
Results: Relative survival at our institution tends to be higher in advanced tumour stages compared to national and international cancer registry data. Nationally we found only little variation in survival rates for low stages CRC (UICC I and II), colon, and rectal cancer. There were notable variations regarding relative survival rates for advanced CRC tumour stages (UICC IV). These variations were even more distinct for rectal cancer after 12, 36 and 60 months (Hildesheim Hospital: 89.9, 40.3, 30.1%; Munich Cancer Registry (MCR): 65.4, 28.7, 16.6%). The international comparison of CRC showed significantly higher relative survival rates for patients with advanced tumour stages after 12 months at our institution (77 vs. 54.9% for UICC IV; raw p<0.001).
Conclusions: Our findings suggest that patients with advanced tumour stages of CRC and especially rectal cancer benefit most from a multidisciplinary and guidelines-oriented treatment at Certified Oncology Centres. For a better evaluation of cancer treatment and improved national and international comparison, the creation of a centralised national cancer registry is necessary.